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Abstract The transdifferentiation of hepatic stellate cells into 
myofibroblast-like cells and the proliferation of the transdiffer-
entiated cells are controlled by TGF-ßl. Little is known about 
the intracellular signal transducers of TGF-ßl. In this paper we 
show that in cultured hepatic stellate cells TGF-ßl induces 
activation of Ras, Raf-1, MEK and MAPK p42 and p44. The 
activation of MAPK depends on the activation of MEK. Our 
data exclude that the observed effects are mediated by a bFGF or 
PDGF autocrine loop. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Hepatic stellate cells (Ito cells, fat-storing cells) play a cen-
tral role in the pathogenesis of liver fibrosis. They transdiffer-
entiate into myofibroblast-like cells, which contribute mainly 
to the excessive collagen synthesis in the liver [1,2]. TGF-ßl is 
involved in the regulation of transdifferentiation and prolifer-
ation as well as in the stimulation of collagen synthesis of the 
myofibroblast-like cells [3-7]. It has been demonstrated that 
TGF-ßl in vitro strongly inhibits the proliferation of hepatic 
stellate cells, but promotes their proliferation in vivo by a 
bFGF or PDGF autocrine loop [8-10]. The collagen synthesis 
is stimulated by TGF-ßl at transcriptional level [11,12]. Re-
cently, Davis et al. [13] reported that in rat hepatic stellate 
cells the protein kinases Raf-1 and MAPK are involved in the 
regulation of collagen gene transcription. However, it remains 
to be elucidated whether they also mediate the TGF-ßl in-
duced effects. 
Little is known about the intracellular transduction of the 
TGF-ßl signal and the regulation of its diverse biological 
effects. The TGF-ßl receptor is a heterodimer of two serine-
threonine kinases, the type I and the type II receptor, which is 
formed upon ligand binding [14,15]. Several isoforms of the 
type I receptor have been described that may activate different 
signal transduction pathways inducing different TGF-ßl re-
sponses [14-16]. The immunophilin FKBP12 and two variants 
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of the Ras-farnesyltransferase a-subunit have been demon-
strated to associate with the type I receptor, but they are 
not involved directly in signal transduction [17-20]. Several 
proteins have been found to become activated by the TGF-
ß receptor kinases, i.e. proteins of the Mad family [16,21,22], 
the TGF-ß activated kinase TAK-1 [23-25] as well as a yet 
unidentified 78 kDa protein kinase [26]. 
Studies on transformed intestinal epithelial cells revealed 
that TGF-ß induces activation of the MAPK isoenzyme p44 
depending on Ras [27-30]. The activation of Ras and MAPK 
p44 induced by TGF-ß has been observed only in sublines 
which were growth-inhibited by TGF-ß but not in TGF-ß-
insensitive cells. This indicates that Ras and MAPK not 
only transduce mitogenic but also growth inhibitory signals 
[28-30]. However, the TGF-ßl induced effects on the activa-
tion of the Ras-MAPK pathway largely depend on the cell 
type investigated. Yan et al. [31] found that in carcinoma cells 
TGF-ßl induces growth inhibition and activation of Ras but 
does not activate MAPK p42 or p44. Contrarily, it has been 
demonstrated in NIH 3T3 cells that TGF-ßl induces activa-
tion of MAPK independently of Ras [32]. In Swiss 3T3 and 
BALB/c 3T3 fibroblasts TGF-ßl does not induce activation of 
MAPK [33]. Moreover, in epithelial cells TGF-ßl suppresses 
the growth factor induced activation of Ras and MAPK [34]. 
In this study, we demonstrate that in cultured stellate cells 
isolated from normal rat liver TGF-ßl induces activation of 
Ras, Raf-1, MEK and MAPK p42 and p44. We show that the 
activation of MAPK p42 and p44 by TGF-ßl requires the 
activation of MEK. Our data exclude that these effects are 
mediated by a bFGF or PDGF autocrine loop. 
2. Materials and methods 
2.1. Materials 
TGF-ßl, bFGF and PDGF-BB and the anti-TGF-ßl antibody 
were purchased from Genzyme (Rüsselsheim, Germany). MBP was 
obtained from Sigma (Munich, Germany). [y-32P]ATP (5000 Ci/ 
mmol) was obtained from Amersham Buchler (Braunschweig, Ger-
many). All inhibitors were purchased from Calbiochem (Bad Soden, 
Germany). Polyclonal anti-MEK antibody and monoclonal anti-c-
Raf-1 antibody were provided by Affiniti (Nottingham, UK). The 
antibodies against bFGF or PDGF-AB were obtained from Biomol 
(Hamburg, Germany). 
2.2. Cell isolation and cultivation 
Hepatic stellate cells were prepared from rat according to Schäfer et 
al. [35]. Male Wistar rats (Charles-River, Sulzfeld, Germany) weighing 
400-500 g were used. Hepatic stellate cells were grown in DMEM 
supplemented with 10% FCS at 37°C under a 5% C02 atmosphere. 
2.3. Treatment of cells and preparation of cell lysates 
Subconfluent cells were growth-arrested by incubation in DMEM 
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Fig. 1. Activation of Ras by TGF-ßl, bFGF and PDGF. Rat hep-
atic stellate cells were labeled with [32P]ortho-phosphate and stimu-
lated with either TGF-ßl (T), bFGF (F) or PDGF (P) for 10 min. 
Ras activity was assessed analyzing the Ras-bound nucleotides by 
thin-layer chromatography (A) and densitometric determination of 
the GTP/GDP ratio (B). 
without FCS 24 h prior to stimulation. The cells were stimulated with 
either TGF-ßl (5 ng/ml), bFGF (25 ng/ml) or PDGF-BB (10 ng/ml) 
for time periods indicated. For antagonizing the effects of bFGF or 
PDGF, the cells were either preincubated with suramine (0.4 mM) for 
4 h or the growth factors were preincubated with anti-bFGF antibody 
or anti-PDGF antibody in 10-fold stoichiometric excess for 1 h prior 
to their addition to the medium. For inhibition of tyrosine kinases the 
cells were preincubated with genistein (40 uM) or tyrphostin A9 (5 
|0,M) for 4 h. MEK was blocked by preincubation of the cells with 
PD98059 (50 uJVI) for 30 min. After stimulation, the cells were washed 
with PBS and lysed in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% 
Triton X-100 (w/v), 0.1 mM Na3V04 , 1 mM PMSF and 0.1 mM 
aprotinin. Cell debris were removed by centrifugation at 15000Xg 
for 30 min at 4°C. Protein concentrations were determined by the 
BioRad protein dye assay. 
2.4. Analysis of Ras bound nucleotides 
The GTP/GDP-ratio of Ras bound nucleotides was determined as 
described previously [36]. The chromatograms were analyzed autora-
diographically in a Phosphorlmager (Molecular Dynamics). 
Fig. 2. Activation of Raf-1 and MEK by TGF-ßl, bFGF and 
PDGF. Rat hepatic stellate cells were stimulated with either TGF-
ßl (T), bFGF (F) or PDGF (P) for 10 min. The activity of Raf-1 
(A) and MEK (B) was assessed by immune complex kinase assay 
using catalytically compromised MEK-1 and MAPK, respectively, 
as specific substrates. 
2.5. Immune complex kinase assay 
The assessment of Raf-1 activity was performed as described pre-
viously [37]. For immunoprecipitation, anti-c-Raf-1 monoclonal anti-
body was used. The kinase reaction was performed in 25 mM PIPES, 
pH 7.0, 2 mM EGTA, 20 mM MgCl2, 5 mM MnCl2, 2 mM DTT, 0.2 
mM Na3VC>4, 0.2 uM okadaic acid using 300 ng recombinant catalyti-
cally compromised MEK-1 as substrate for Raf-1. The assessment of 
MEK activity was performed according to Lange-Carter et al. [38]. 
The lysis buffer was supplemented with 10% glycerol (w/v). For im-
munoprecipitation, anti-MEK-1,2 polyclonal antibody was used. The 
kinase assays were analyzed autoradiographically in a Phosphorlmag-
er (Molecular Dynamics). 
2.6. In vitro renaturation assay for MAPK activity 
MAPK activity was assessed by an in vitro renaturation assay (in-
gel kinase assay) as described previously [37]. After the denaturation-
renaturation procedure, the gels were preincubated in 25 mM HEPES, 
pH 7.4, 2 mM 2-mercaptoethanol, 10 mM MgCl2, 0.1 mM Na3V04 , 
and 0.5 mM EGTA at 30°C for 30 min. The kinase reaction was 
performed by incubation of the gels in 25 mM HEPES, pH 7.4, 
2 mM 2-mercaptoethanol, 10 mM MgCl2, 0.1 mM Na3V04 , 0.5 mM 
EGTA, 25 itM ATP and 250 itCi [y-32P]ATP. 
3. Results and discussion 
3.1. TGF-fil induces activation of Ras 
We assessed the activation of Ras in cultured stellate cells 
isolated from normal rat liver following stimulation with 
T G F - ß l , b F G F or P D G F for 10 min. Densitometric analysis 
of Ras-bound nucleotides revealed that T G F - ß l induces rapid 
activation of Ras by approximately 6-fold to about the same 
extent as observed for b F G F and P D G F (Fig. 1). 
3.2. TGF-fil induces activation of Raf-1 and MEK 
Ras is known to be involved in the activation of Raf-1, 
which in turn activates M E K . We were therefore interested 
in whether T G F - ß l also activates Raf-1 and M E K . We exam-
Fig. 3. Activation of MAPK by TGF-ßl, bFGF and PDGF. Rat hepatic stellate cells were treated with either TGF-ßl (T), bFGF (F) or 
PDGF-BB (P) for indicated time periods. MAPK activity was assessed by an in vitro renaturation assay using myelin basic protein as sub-
strate. 
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Fig. 4. Inhibition of MAPK activation induced by TGF-ßl, bFGF 
and PDGF. Rat hepatic stellate cells were preincubated with PD 
98059 for 30 min and stimulated with either TGF-ßl (T), bFGF (F) 
or PDGF (P) for 10 min. MAPK activity was assessed by an in vi-
tro renaturation assay. 
ined the activity of Raf-1 and MEK by immune complex 
kinase assays in lysates of hepatic stellate cells which were 
stimulated with either TGF-ßl, bFGF or PDGF. TGF-ßl 
was found to activate Raf-1 and MEK, but to a lesser extent 
than their activation by bFGF or PDGF (Fig. 2). 
3.3. TGF-ßl induces activation of MAPK p42 and p44 
It has been demonstrated in transformed epithelial and 
NIH3T3 cells that TGF-ßl activates MAPK [29,30,32]. How-
ever, in Swiss 3T3 cells or even in epithelial cell lines other 
groups found no TGF-ßl induced activation of MAPK 
[31,33]. We examined MAPK activation by an in vitro rena-
turation assay in lysates of hepatic stellate cells stimulated 
with TGF-ßl, bFGF or PDGF. We found that TGF-ßl as 
well as bFGF and PDGF induce activation of MAPK p42 
and p44. However, as observed for Raf-1 and MEK, the ex-
tent of the MAPK activation by TGF-ßl was substantially 
weaker as compared to its activation by the growth factors 
bFGF or PDGF (Fig. 3). The time course of MAPK activa-
tion demonstrates that MAPK p42 and p44 are already fully 
activated by TGF-ßl, bFGF or PDGF after 5 min and persist 
up to 8 h in the activated state in presence of TGF-ßl. 
In order to investigate whether the TGF-ßl induced activa-
tion of MAPK depends on MEK, we preincubated the cells 
with PD 98059, which is described to inhibit MEK [39]. This 
results in complete suppression of the MAPK activation in-
duced by TGF-ßl as well as by bFGF or PDGF (Fig. 4) and 
shows that activation of MEK is a prerequisite for activation 
of MAPK by TGF-ßl. 
3.4. Activation of MAPK by TGF-$1 occurs independently of 
autocrine bFGF or PDGF 
The activation of MAPK occurs rapidly and hence auto-
crine growth stimulation is not likely. In order to get further 
evidence that the activation of MAPK by TGF-ßl is not 
mediated by an autocrine loop involving bFGF or PDGF, 
the cells were preincubated with suramine, which is known 
to inhibit the binding of various growth factors to their cell 
surface receptors [40]. Suramine did not affect the activation 
of MAPK induced by TGF-ßl but suppressed completely the 
activation of MAPK by bFGF or PDGF (Fig. 5A). Further, 
specific inhibition of bFGF or PDGF by antibodies antago-
nizing their mitogenic effects did not block the TGF-ßl in-
duced activation of MAPK but diminished substantially the 
activation of MAPK by bFGF and PDGF (Fig. 5B). Finally, 
the inhibition of tyrosine kinases with genistein or tyrphostin 
A9 completely abrogated the activation of MAPK by bFGF 
or PDGF, but did not affect the TGF-ßl induced activation 
of MAPK (Fig. 5C). This indicates that the activation of 
MAPK by TGF-ßl is independent of tyrosine kinases. This 
observation is somewhat intriguing, since the phosphorylation 
of tyrosine-340 in Raf-1 has been shown to be important in 
the activation of Raf-1 via Ras [41]. However, it remains to be 
elucidated whether the TGF-ßl induced activation of Raf-1 
requires Ras. It has been demonstrated that Raf-1 can also be 
activated independently of Ras and tyrosine kinases by pro-
tein kinase C [42]. 
Thus, in hepatic stellate cells TGF-ßl may activate Raf-1, 
Fig. 5. Effects of suramine, neutralizing antibodies of bFGF and PDGF and inhibitors of tyrosine kinases on TGF-ßl induced activation of 
MAPK. A: Rat hepatic stellate cells were preincubated with suramine for 4 h and then stimulated with either TGF-ßl (T), bFGF (F) or 
PDGF (P), B: TGF-ßl (T), bFGF (F) and PDGF (P) were preincubated for 1 h with neutralizing antibodies in 10-fold stoichiometric excess 
prior to their addition to the medium. C: Rat hepatic stellate cells were pretreated with either genistein or tyrphostin A 9 for 4 h and then 
stimulated with either TGF-ßl (T), bFGF (F) or PDGF (P). MAPK activity was assessed by an in vitro renaturation assay. 
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M E K and M A P K not exclusively via Ras or may even acti-
vate Raf-1 and Ras independently from each other. Moreover, 
it remains to be established whether in hepatic stellate cells 
M E K and M A P K are activated via Raf-1 or via other path-
ways. It has been shown that in hepatic stellate cells Raf-1 
and M A P K differentially regulate collagen gene expression 
[13]. 
The activation of different pathways could also reflect the 
different effects of T G F - ß l on cell growth, differentiation and 
transcriptional activation. Although it has been demonstrated 
that Ras and M A P K mediate at least in part the TGF-ß-
induced growth inhibition in transformed epithelial cells 
[30], it has to be clarified whether in hepatic stellate cells 
Ras , Raf-1, M E K and M A P K might also be involved in the 
stimulation of collagen gene expression by T G F - ß l . 
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